Deep search
Search
Images
Copilot
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly shares drop
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Crohn's disease, FDA and Lilly
US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease (IBD). The drug, branded as Omvoh,
Eli Lilly’s Omvoh for Crohn’s disease approved by FDA
Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh
Lilly’s Omvoh approved by FDA for Crohn’s
The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success in diabetes and obesity.
1d
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
STAT
23h
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
2d
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday ...
1d
Has Eli Lilly Stock Peaked?
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
1d
on MSN
Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
2d
Eli Lilly Shares Down 7.5% as Market Reacts to Slashed Q4 Forecast
Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for ...
FiercePharma
1d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Insider Monkey
2d
Why Eli Lilly (LLY) Stock Is Declining Today
The shares of pharmaceutical giant
Eli
Lilly
(LLY) are falling 5% today after the company preannounced ...
1d
Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
Scorpion Therapeutics
Q4
Mounjaro
Outlook
Feedback